Purpose of Review <p>Obesity-related metabolic disorders such as metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic syndrome (MetS), and type 2 diabetes mellitus (T2DM) have traditionally been treated as separate conditions. This review aims to present a unified conceptual framework in which these disorders are viewed as progressive stages within a continuous and dynamic process of metabolic dysfunction. The goal is to clarify the shared mechanisms underlying this progression and to explore the clinical value of approaching them as a continuum.</p> Recent Findings <p>Insulin resistance, chronic low-grade inflammation, adipokine imbalance, and ectopic fat accumulation are common drivers across all stages of metabolic deterioration. These processes are reinforced by coordinated dysfunction in adipose tissue, liver, skeletal muscle, pancreas, and the gut microbiota. Longitudinal and genetic studies support a typical progression from individuals with obesity to MAFLD, then to MetS and T2DM, although individual trajectories vary. Certain phenotypes such as metabolically healthy individuals with obesity and normal-weight individuals with visceral adiposity illustrate the spectrum’s heterogeneity. Early dysfunction is often reversible through lifestyle or pharmacologic intervention, underscoring the importance of timely detection.</p> Summary <p>Reframing obesity-associated metabolic disorders as a continuous disease process enables more accurate risk assessment, earlier intervention, and coordinated care strategies. This integrated perspective supports a shift toward mechanism-based and individualized treatment, with the potential to reduce risk and delay progression to advanced metabolic disease and its complications.</p>